Imagine if we could grow fabric colors in a lab using bacteria instead of mixing toxic chemicals from oil. This team uses a digital blueprint to program these bacteria to eat waste and turn it into high-quality dyes. It is like switching from a chemical factory to a biological brewery that makes the same vibrant colors without the pollution.
The textile industry relies on oil-derived dyes and toxic chemicals like aniline, leading to massive water pollution and health hazards. Existing natural alternatives fail because they perform poorly and are not sustainable at scale.
A proprietary Synthetic Genomics Platform (SGP) and a bio-production process that converts biomass waste into high-performance textile dyes.
If you are a denim brand dealing with the toxic footprint of indigo dyes — this project developed a bio-produced indigo blue that provides the same performance as synthetic dyes. It removes the need for carcinogenic chemicals like aniline and cyanide.
If you are a dyeing house dealing with strict pollution regulations and oil-price volatility — this project developed a plug-and-play dye solution. It requires no equipment changes to your existing supply-chain processes.
If you are a waste processor dealing with low-value organic streams — this project developed methods to valorize low-cost waste as raw material for high-value dyes. This turns a waste liability into a profitable industrial feedstock.
The proprietary Synthetic Genomics Platform (SGP) enables more than a 10-fold reduction in both the time and costs for strain development. Additionally, the process uses low-cost waste as raw material to keep prices competitive.
Yes, the project uses a 'plug & play' solution that requires no process or equipment changes for the fashion industry's supply chain. The goal is to achieve 50% market share at one large denim target.
The company utilizes a proprietary Synthetic Genomics Platform (SGP) based on deep-tech computational and genomic tools to engineer bacteria.
It eliminates dependence on oil derivatives and toxic chemicals like aniline, which is a Group B2 human carcinogen, reducing the risk of pollution and regulatory penalties.
Based on the objective, the company aims to reach €24M in revenues by 2026.
The project is led by a single SME, SYNOVANCE from France, which holds 100% of the industry ratio. This indicates a highly streamlined, commercially-driven execution model without the complexity of academic partners, focusing entirely on the industrial application of their Synthetic Genomics Platform.
Contact SYNOVANCE in France regarding their Synthetic Genomics Platform
Contact us to find partners for bio-based textile integration
